Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations


October 15, 2013
Science Signaling

Researchers accrued a library of natural products and performed a screen to identify molecular targets.

October 14, 2013
Cancer Cell

Researchers document coexpression of EGFR and EGFRvIII in primary human glioblastoma that drives transformation and tumorigenesis in a cell-intrinsic manner and clarify specific oncogenic signaling relationships in glioblastoma.

October 04, 2013
Clinical Cancer Research

Author comment on Dual blockade of the PI3K/AKT/mTOR(AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergystically inhibits rhabdomyosarcoma... 

October 01, 2013
Nature Genetics

A collaborative effort to compare the molecular changes across the original 12 tumor types profiled by The Cancer Genome Atlas.

October 01, 2013
Cold Spring Harbor Perspective in Medicine

A review on the role of MYCN and other newly identifed drivers in neuroblastoma.

September 11, 2013
Journal of the American Chemical Society

Using a newly developed platform to identify the signaling pathway/molecular target of natural products, we identified a family of alkaloid natural products, discoipyrroles A-D (1-4), from Bacillus hunanensis that inhibit the DDR2 signaling pathway. 

September 01, 2013
Cancer Discovery

3q26 is frequently amplified in several cancer types with a common amplified region containing 20 genes. To identify cancer driver genes in this region, we interrogated the function of each of these genes.

August 29, 2013

The Cancer Therapeutics Response Portal ( was created to identify cancer genotype-compound sensitivity relationships.

August 15, 2013

Researchers introduce the PiHelper, which integrates human drug-target and antibody-target associations from publicly available resources to help meet the needs of researchers in systems pharmacology, perturbation biology and proteomics.